Characterizing alpha helical properties of Ebola viral proteins as potential targets for inhibition of alpha-helix mediated protein-protein interactions

F1000Research

Volumn 3, Issue , 2015, Pages

  Chakraborty, Sandeep ^a,b   Rao, Basuthkar J ^b   Asgeirsson, Bjarni ^c   Dandekar, Abhaya ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TATA INSTITUTE OF FUNDAMENTAL RESEARCH   (India)

^c UNIVERSITY OF ICELAND   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MEMBRANE FUSION PROTEIN; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN;

ALPHA HELIX; ARTICLE; COMPUTER PROGRAM; EBOLA VIRUS; ENZYME INHIBITION; HUMAN; HYDROPHOBICITY; MARBURG VIRUS; NONHUMAN; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; PROTEIN TARGETING; SPECIES COMPARISON; VIRUS VIRULENCE;

EID: 84925014192     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.5573.3     Document Type: Article

References (56)

1. Pattyn S van der Groen G Courteille G: Isolation of Marburg-like virus from a case of haemorrhagic fever in Zaire. Lancet. 1977;1(8011):573-574. 65663 10.1016/S0140-6736(77)92002-5
2. Colebunders R Borchert M: Ebola haemorrhagic fever-a review. J Infect. 2000;40(1):16-20. 10762106 10.1053/jinf.1999.0603
3. Piot P: Ebola's perfect storm. Science. 2014;345(6202):1221. 25214580 10.1126/science.1260695
4. Piot P Muyembe JJ Edmunds WJ: Ebola in west Africa: from disease outbreak to humanitarian crisis. Lancet Infect Dis. 2014;14(11):1034-1035. 25282665 10.1016/S1473-3099(14)70956-9
5. Kiley M Bowen E Eddy G: Filoviridae: a taxonomic home for Marburg and Ebola Viruses? Intervirology. 1982;18(1-2):24-32. 7118520 10.1159/000149300
6. Daugherty MD Malik HS: How a virus blocks a cellular emergency access lane to the nucleus, STAT! Cell Host Microbe. 2014;16(2):150-152. 25121743 10.1016/j.chom.2014.07.013
7. Elliott LH Kiley MP McCormick JB: Descriptive analysis of Ebola virus proteins. Virology. 1985;147(1):169-176. 4060597 10.1016/0042-6822(85)90236-3
8. Bornholdt ZA Noda T Abelson DM: Structural basis for ebolavirus matrix assembly and budding; protein plasticity allows multiple functions. Cell. 2013;154:763. 23953110 10.1016/j.cell.2013.07.015 4138722
9. Radzimanowski J Effantin G Weissenhorn W: Conformational plasticity of the Ebola virus matrix protein. Protein Sci. 2014;23(11):1519-1527. 25159197 10.1002/pro.2541
10. Wild CT Shugars DC Greenwell TK: Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A. 1994;91(21):9770-9774. 7937889 10.1073/pnas.91.21.9770 44898
11. Judice JK Tom JY Huang W: Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism. Proc Natl Acad Sci U S A. 1997;94(25):13426-13430. 9391041 10.1073/pnas.94.25.13426 28321
12. Ernst JT Kutzki O Debnath AK: Design of a protein surface antagonist based on α-helix mimicry: inhibition of gp41 assembly and viral fusion. Angew Chem Int Ed Engl. 2002;41(2):278-281. 12491408 10.1002/1521-3773(20020118)41:2&278::AID-ANIE278&3.0.CO;2-A
13. Jones MK Anantharamaiah GM Segrest JP: Computer programs to identify and classify amphipathic alpha helical domains. J Lipid Res. 1992;33(2):287-296. 1569380
14. Chakraborty S Rao B Dandekar A: Pagal - Properties and corresponding graphics of alpha helical structures in proteins. F1000Res. 2014;3:206. 25352981 10.12688/f1000research.4952.2 4207245
15. Joosten RP te Beek TA Krieger E: A series of PDB related databases for everyday needs. Nucleic Acids Res. 2011;39(Database issue):D411-419. 21071423 10.1093/nar/gkq1105 3013697
16. Weissenhorn W Carfi A Lee KH: Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol Cell. 1998;2(5):605-616. 9844633 10.1016/S1097-2765(00)80159-8
17. Lee JE Fusco ML Hessell AJ: Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature. 2008;454(7201):177-182. 18615077 10.1038/nature07082 2700032
18. Xu W Edwards MR Borek DM: Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe. 2014;16(2):187-200. 25121748 10.1016/j.chom.2014.07.008 4188415
19. Reid SP Leung LW Hartman AL: Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol. 2006;80(11):5156-5167. 16698996 10.1128/JVI.02349-05 1472181
20. Azzarito V Long K Murphy NS: Inhibition of α-helix-mediated protein-protein interactions using designed molecules. Nat Chem. 2013;5(3):161-173. 23422557 10.1038/nchem.1568
21. Suzuki Y Gojobori T: The origin and evolution of Ebola and Marburg viruses. Mol Biol Evol. 1997;14(8):800-806. 9254917 10.1093/oxfordjournals.molbev.a025820
22. Feldmann H Nichol ST Klenk HD: Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology. 1994;199(2):469-473. 8122375 10.1006/viro.1994.1147
23. Larkin MA Blackshields G Brown NP: Clustal W and Clustal X version 2.0. Bioinformatics. 2007;23(21):2947-2948. 17846036 10.1093/bioinformatics/btm404
24. Gouy M Guindon S Gascuel O: SeaView version 4: A multiplatform graphical user interface for sequence alignment and phylogenetic tree building. Mol Biol Evol. 2010;27(2):221-224. 19854763 10.1093/molbev/msp259
25. Konagurthu AS Whisstock JC Stuckey PJ: MUSTANG: a multiple structural alignment algorithm. Proteins. 2006;64(3):559-574. 16736488 10.1002/prot.20921
26. Badani H Garry RF Wimley WC: Peptide entry inhibitors of enveloped viruses: the importance of interfacial hydrophobicity. Biochim Biophys Acta. 2014;1838(9):2180-97. 24780375 10.1016/j.bbamem.2014.04.015
27. Weissenhorn W Calder LJ Wharton SA: The central structural feature of the membrane fusion protein subunit from the Ebola virus glycoprotein is a long triple-stranded coiled coil. Proc Natl Acad Sci U S A. 1998;95(11):6032-6036. 9600912 10.1073/pnas.95.11.6032 27580
28. Zhang AP Bornholdt ZA Liu T: The Ebola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold. PLoS Pathog. 2012;8(2):e1002550. 22383882 10.1371/journal.ppat.1002550 3285596
29. Chakraborty S Rao B Asgeirsson B: Correlating the ability of VP24 protein from Ebola and Marburg viruses to bind human karyopherin to their immune suppression mechanism and pathogenicity using computational methods [v1; ref status: awaiting peer review, http://f1000r.es/4o3]. F1000Res. 2014;3:265. 10.12688/f1000research.5666.1
30. Miranda ME White ME Dayrit MM: Seroepidemiological study of filovirus related to Ebola in the Philippines. Lancet. 1991;337(8738):425-426. 1671441 10.1016/0140-6736(91)91199-5
31. Miranda ME Miranda NL: Reston Ebolavirus in humans and animals in the Philippines: a review. J Infect Dis. 2011;204(Suppl 3):S757-S760. 21987747 10.1093/infdis/jir296
32. Valmas C Grosch MN Schumann M: Marburg virus evades interferon responses by a mechanism distinct from Ebola virus. PLoS Pathog. 2010;6(1):e1000721. 20084112 10.1371/journal.ppat.1000721 2799553
33. Leung DW Ginder ND Fulton DB: Structure of the Ebola VP35 interferon inhibitory domain. Proc Natl Acad Sci U S A. 2009;106(2):411-416. 19122151 10.1073/pnas.0807854106 2626716
34. Kimberlin CR Bornholdt ZA Li S: Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression. Proc Natl Acad Sci U S A. 2010;107(1):314-319. 20018665 10.1073/pnas.0910547107 2806767
35. Steegborn C Danot O Huber R: Crystal structure of transcription factor malt domain iii: a novel helix repeat fold implicated in regulated oligomerization. Structure. 2001;9(11):1051-1060. 11709169 10.1016/S0969-2126(01)00665-7
36. Subbotina E Dadaeva A Kachko A: Genetic factors of Ebola virus virulence in guinea pigs. Virus Res. 2010;153(1):121-133. 20654661 10.1016/j.virusres.2010.07.015
37. Brown CS Lee MS Leung DW: In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity. J Mol Biol. 2014;426(10):2045-2048. 24495995 10.1016/j.jmb.2014.01.010
38. Ekins S Freundlich JS Coffee DW: A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus [v2; ref status: indexed, http://f1000r.es/4wt]. F1000 Res. 2014;3:277. 10.12688/f1000research.5741.2
39. Uversky VN: Intrinsically disordered proteins from A to Z. Int J Biochem Cell Biol. 2011;43(8):1090-1103. 21501695 10.1016/j.biocel.2011.04.001
40. Cook JD Lee JE: The secret life of viral entry glycoproteins: moonlighting in immune evasion. PLoS Pathog. 2013;9(5):e1003258. 23696729 10.1371/journal.ppat.1003258 3656028
41. Dziubanska PJ Derewenda U Ellena JF: The structure of the C-terminal domain of the Zaire ebolavirus nucleoprotein. Acta Crystallogr D Biol Crystallogr. 2014;70(Pt 9):2420-2429. 25195755 10.1107/S1399004714014710 4157450
42. Uversky VN: The alphabet of intrinsic disorder: II. various roles of glutamic acid in ordered and intrinsically disordered proteins. Intrinsically Disord Proteins. 2013;1:18-40. 10.4161/idp.24684
43. Kash JC Mühlberger E Carter V: Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type i interferon response is associated with enhanced virulence. J Virol. 2006;80(6):3009-3020. 16501110 10.1128/JVI.80.6.3009-3020.2006 1395418
44. Wells JA McClendon CL: Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature. 2007;450(7172):1001-1009. 18075579 10.1038/nature06526
45. Hartlieb B Modrof J Mühlberger E: Oligomerization of Ebola virus VP30 is essential for viral transcription and can be inhibited by a synthetic peptide. J Biol Chem. 2003;278(43):41830-41836. 12912982 10.1074/jbc.M307036200
46. Ghanem A Mayer D Chase G: Peptide-mediated interference with influenza A virus polymerase. J Virol. 2007;81(14):7801-7804. 17494067 10.1128/JVI.00724-07 1933368
47. Chapman RN Dimartino G Arora PS: A highly stable short alpha-helix constrained by a main-chain hydrogen-bond surrogate. J Am Chem Soc. 2004;126(39):12252-12253. 15453743 10.1021/ja0466659
48. Bird GH Madani N Perry AF: Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. Proc Natl Acad Sci U S A. 2010;107(32):14093-14098. 20660316 10.1073/pnas.1002713107 2922607
49. Bird GH Boyapalle S Wong T: Mucosal delivery of a double-stapled RSV peptide prevents nasopulmonary infection. J Clin Invest. 2014;124(5):2113-24. 24743147 10.1172/JCI71856 4001541
50. Harrison RS Shepherd NE Hoang HN: Downsizing human, bacterial, and viral proteins to short water-stable alpha helices that maintain biological potency. Proc Natl Acad Sci U S A. 2010;107(26):11686-11691. 20543141 10.1073/pnas.1002498107 2900680
51. Takada A Feldmann H Stroeher U: Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol. 2003;77(2):1069-1074. 12502822 10.1128/JVI.77.2.1069-1074.2003 140786
52. Wilson JA Hevey M Bakken R: Epitopes involved in antibody-mediated protection from Ebola virus. Science. 2000;287(5458):1664-1666. 10698744 10.1126/science.287.5458.1664
53. Takada A Ebihara H Jones S: Protective efficacy of neutralizing antibodies against Ebola Virus infection. Vaccine. 2007;25(6):993-999. 17055127 10.1016/j.vaccine.2006.09.076
54. Qiu X Alimonti JB Melito PL: Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol. 2011;141(2):218-227. 21925951 10.1016/j.clim.2011.08.008
55. Qiu X Wong G Audet J: Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514(7520):47-53. 25171469 10.1038/nature13777 4214273
56. Olinger GG Jr Pettitt J Kim D: Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A. 2012;109(44):18030-18035. 23071322 10.1073/pnas.1213709109 3497800